Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus CARDIZEM LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus CARDIZEM LA.
AFEDITAB CR vs CARDIZEM LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Terminal elimination half-life: 5-8 hours after oral administration. For extended-release formulations, the half-life is similar but the prolonged absorption phase results in sustained plasma concentrations.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Urine (2-4% unchanged, ~40% as metabolites); bile/feces (major route, ~60% as metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker